Lazard Asset Management’s Denali Therapeutics DNLI Stock Holding History

Lazard Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,410	Closed	-$90K	–	2279
2024 Q1	$90K	Hold	4,410	–	–	﹤0.01%	1573
2023 Q4	$94K	Sell	4,410 -6,451	-59%	-$128K	﹤0.01%	1681
2023 Q3	$223K	Buy	10,861 +5,916	+120%	+$150K	﹤0.01%	1354
2023 Q2	$145K	Buy	4,945 +2,025	+69%	+$56.9K	﹤0.01%	1441
2023 Q1	$67K	Sell	2,920 -2,433	-45%	-$67K	﹤0.01%	1687
2022 Q4	$148K	Hold	5,353	–	–	﹤0.01%	1372
2022 Q3	$164K	Hold	5,353	–	–	﹤0.01%	1316
2022 Q2	$157K	Buy	+5,353	New	+$140K	﹤0.01%	1348
2021 Q4	–	Sell	-1,186	Closed	-$59K	–	2322
2021 Q3	$59K	Buy	+1,186	New	+$66.8K	﹤0.01%	1601
2021 Q2	–	Sell	-833	Closed	-$47K	–	1985
2021 Q1	$47K	Buy	+833	New	+$55.8K	﹤0.01%	1453
2020 Q1	–	Sell	-1,073	Closed	-$18K	–	1611
2019 Q4	$18K	Buy	+1,073	New	+$17.9K	﹤0.01%	1254

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Lazard Asset Management's DNLI Position: Q2 2024 in Review

Lazard Asset Management sold out of Denali Therapeutics (DNLI) in Q2 2024, closing a stake of 4,410 shares — an estimated $90K sold.

Lazard Asset Management first reported a position in DNLI in Q4 2019 and held it in 11 quarters. The position peaked at $223K in Q3 2023. 203 funds tracked by Wall St. Rank hold DNLI as of Q2 2024.

Lazard Asset Management reported no remaining Denali Therapeutics position as of Q2 2024 after selling out during the quarter.
Lazard Asset Management sold 4,410 Denali Therapeutics shares in Q2 2024, an estimated $90K.
Lazard Asset Management first reported a position in Denali Therapeutics in Q4 2019 and held it in 11 quarters.
Lazard Asset Management's Denali Therapeutics position peaked at $223K in Q3 2023.
203 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2024.

Based on Lazard Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.